Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 1, 2010, Pages 14-22

  Michalski, Jeff M ^a   Bae, Kyounghwa ^b   Roach, Mack ^c   Markoe, Arnold M ^d   Sandler, Howard M ^e   Ryu, Janice ^f   Parliament, Matthew B ^g   Straube, William ^h   Valicenti, Richard K ⁱ   Cox, James D ^j  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h Image Guided Therapy Center   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3D CONFORMAL RADIATION THERAPY; DOSE ESCALATION; DOSE LEVELS; DOSE-ESCALATION STUDY; GENITOURINARY TOXICITIES; HAZARD RATIO; HIGH DOSE; INCIDENCE RATE; PROSTATE CANCERS; SEMINAL VESICLE; THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY; UP PERIOD;

RADIOTHERAPY; THREE DIMENSIONAL; TOXICITY;

FLUORINE CONTAINING POLYMERS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SEMINAL VESICLE;

AGED; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; SEMINAL VESICLES; TREATMENT OUTCOME; TUMOR BURDEN; URINARY BLADDER; UROGENITAL SYSTEM;

EID: 72149128943     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.062     Document Type: Article

References (21)

1. Michalski J., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46 (2000) 391-402
2. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
3. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 58 (2004) 735-742
4. In: Beahrs O., Henson D., Hutter R., et al. (Eds). AJCC cancer staging manual. 4th ed (1992), Lippincott-Raven, Philadelphia
5. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54 (2002) 1036-1046
6. International Commission on Radiation Units and Measurement. ICRU Report 50. Prescribing, recording, and reporting photon beam therapy (1993), ICRU, Bethesda, MD
7. Diaz A., Roach M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
8. Roach III M. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 1923-1924
9. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 35 (1996) 251-257
10. Cox D.R. Regression models and life tables. J Royal Stat Soc B 34 (1972) 187-229
11. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabailit [Statistic theory of the classes and probability calculus.]. Pubblicazioni del R Istituto Superiore di Scienze Economiche di Firenze 1936;8:3-62.
12. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
13. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
14. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
15. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
16. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1124-1129
17. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
18. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
19. King C.R., and Fowler J.F. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51 (2001) 213-214
20. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
21. Madsen B.L., Hsi R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007) 1099-1105